{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:56:14Z","timestamp":1790733374820,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T00:00:00Z","timestamp":1608508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NeraCare GmbH"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejca.2020.10.016","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T06:32:07Z","timestamp":1606890727000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I\u2013III patients"],"prefix":"10.1016","volume":"143","author":[{"given":"Thilo","family":"Gambichler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsagoudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Kiecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eggert","family":"Stockfleth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Hamscho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2516-5181","authenticated-orcid":false,"given":"Teresa","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ejca.2020.10.016_bib1","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2020.10.016_bib2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2020.10.016_bib3","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2020.10.016_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-018-0048-5","article-title":"The new era of adjuvant therapies for melanoma","volume":"15","author":"Eggermont","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2020.10.016_bib5","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-18-1550","article-title":"Immunotherapy of melanoma: facts and hopes","volume":"25","author":"Weiss","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2020.10.016_bib6","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1016\/S1470-2045(18)30596-5","article-title":"Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?","volume":"19","author":"Grob","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.10.016_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ctrv.2018.06.003","article-title":"It is finally time for adjuvant therapy in melanoma","volume":"69","author":"Napolitano","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.ejca.2020.10.016_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/14737159.2016.1126511","article-title":"Prognostic and predictive biomarkers in melanoma: an update","volume":"16","author":"Foth","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"issue":"6","key":"10.1016\/j.ejca.2020.10.016_bib9","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.ejca.2020.10.016_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/ITT.S134842","article-title":"Melanoma treatment in review","volume":"7","author":"Domingues","year":"2018","journal-title":"ImmunoTargets Ther"},{"issue":"3","key":"10.1016\/j.ejca.2020.10.016_bib11","first-page":"29","article-title":"BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management","volume":"3","author":"Livingstone","year":"2014","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.016_bib12","doi-asserted-by":"crossref","first-page":"5361569","DOI":"10.1155\/2016\/5361569","article-title":"Cutaneous side effects of BRAF inhibitors in advanced melanoma: review of the literature","volume":"2016","author":"Gencler","year":"2016","journal-title":"Dermatol Res Pract"},{"issue":"2","key":"10.1016\/j.ejca.2020.10.016_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2020.10.016_bib14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1080\/14737140.2016.1249856","article-title":"Nivolumab in melanoma","volume":"16","author":"Specenier","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1016\/j.ejca.2020.10.016_bib15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2016.10.018","article-title":"Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013","volume":"76","author":"Landow","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2020.10.016_bib16","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/jid.2014.452","article-title":"More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland, Australia","volume":"135","author":"Whiteman","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.ejca.2020.10.016_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/CAD.0000000000000628","article-title":"Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands","volume":"29","author":"Franken","year":"2018","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejca.2020.10.016_bib18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2016.06.002","article-title":"Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges","volume":"48","author":"Tartari","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.ejca.2020.10.016_bib19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1309\/AJCPG83CMAVFBWLC","article-title":"Clinical characteristics and survival data of melanoma patients with nevus cell aggregates within sentinel lymph nodes","volume":"139","author":"Gambichler","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2020.10.016_bib20","doi-asserted-by":"crossref","first-page":"pky032","DOI":"10.1093\/jncics\/pky032","article-title":"A prognostic gene signature expressed in primary cutaneous melamona: synergism with conventional staging","volume":"2","author":"Brunner","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.ejca.2020.10.016_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canep.2014.10.010","article-title":"Incidence and survival in patients with cutaneous melanoma by morphology, anatomical site and TNM stage: a Danish Population-based Register Study 1989-2011","volume":"39","author":"Bay","year":"2015","journal-title":"Cancer Epidemiol"},{"issue":"12","key":"10.1016\/j.ejca.2020.10.016_bib22","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1002\/ijc.30407","article-title":"Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence","volume":"139","author":"Rockberg","year":"2016","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2020.10.016_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2020.10.016_bib24","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/jid.2014.85","article-title":"Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease","volume":"134","author":"Sivendran","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2020.10.016_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13000-018-0690-3","article-title":"Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients","volume":"13","author":"Cook","year":"2018","journal-title":"Diagn Pathol"},{"issue":"12","key":"10.1016\/j.ejca.2020.10.016_bib26","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1097\/DSS.0000000000001588","article-title":"Estimation of prognosis in invasive cutaneous melanoma: an independent study of the accuracy of a gene expression profile test","volume":"44","author":"Greenhaw","year":"2018","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.ejca.2020.10.016_bib27","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/cam4.2128","article-title":"Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma","volume":"8","author":"Keller","year":"2019","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.ejca.2020.10.016_bib28","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1158\/1078-0432.CCR-18-2847","article-title":"Validation of melanoma immune profile (MIP), a prognostic immune gene prediction score for stage II-III melanoma","volume":"25","author":"Gartrell","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2020.10.016_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/PO.19.00206","article-title":"Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma","author":"Bellomo","year":"2020","journal-title":"JCO Precis Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920312752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920312752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:29:09Z","timestamp":1760732949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920312752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":29,"alternative-id":["S0959804920312752"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I\u2013III patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}